Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2023 · fourth_quarter · 4T
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Did not lobby on banking
Source: Senate LDA
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Preparedness and Response Reauthorization Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Preparedness and Response Reauthorization Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Pharmacy Benefit Manager Transparency Act of 2023
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Transparency Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill.
Pharmacy Benefit Manager Transparency Act of 2023
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Transparency Act of 2023
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Transparency Act of 2023
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate.
Pharmacy Benefit Manager Transparency Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Pharmacy Benefit Manager Transparency Act of 2023
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Transparency Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Pharmacy Benefit Manager Reform Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Reform Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Pharmacy Benefit Manager Reform Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate.
Pandemic and All-Hazards Preparedness and Response Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Pandemic and All-Hazards Preparedness and Response Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
American Innovation and Jobs Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
American Innovation and Jobs Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
American Innovation and Jobs Act
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing provisions
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing implementation
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B Program
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues 340B Program
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Amendments of 2022
Client: CALIFORNIA LIFE SCIENCES · Firm: HAGGERTY POLICY SOLUTIONS
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing implementation
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing provisions
Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Client: AMGEN · Firm: HAGGERTY POLICY SOLUTIONS
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B Program
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues 340B Program
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Lobbied to discuss with Congress the U.S. Trade Representative (USTR) delay on the decision to expand a World Trade Organization intellectual property waiver for COVID-19 vaccines to include COVID diagnostics and therapeutics and how the waiver should not be agreed to. Including potential amendments to the FY24 NDAA reauthorization bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2023 · fourth_quarter · 4T
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2023 · fourth_quarter · Q4
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2023 · third_quarter · Q3
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2023 · second_quarter · Q2
Silicon Valley Bank collapse - Congressional oversight and potential action on policy issues surrounding the collapse.
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Lobbied to discuss with Congress the U.S. Trade Representative (USTR) delay on the decision to expand a World Trade Organization intellectual property waiver for COVID-19 vaccines to include COVID diagnostics and therapeutics and how the waiver should not be agreed to. Including potential amendments to the FY24 NDAA reauthorization bill.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2023 · second_quarter · Q2
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2023 · first_quarter · Q1
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill.
AMGEN via HAGGERTY POLICY SOLUTIONS
2023 · first_quarter · Q1
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate.
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2022 · fourth_quarter · Q4
R&D Tax Credit Reauthorization Orphan drug tax credit generally
Inflation Reduction Act - all drug pricing implementation CMS proposed rule on Transitional Coverage of Emerging Technologies (TCET) Administration's EO on Prescription Drug Pricing
Administration's support of WTO proposal on TRIPS waiver for COVID vaccines and therapies
AMGEN via HAGGERTY POLICY SOLUTIONS
2022 · fourth_quarter · Q4
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues 340B Program
S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2022 · third_quarter · 3A
Administration's support of WTO proposal on TRIPS waiver for COVID vaccines and therapies
R&D Tax Credit Reauthorization Orphan drug tax credit generally
FDA User Fee Reauthorization Act of 2022 - Reauthorization of PDUFA, MDUFA, and BSFUA - Accelerated approval, clinical trial diversity, medtech issues such as change control plans and foreign inspections certificates COVID 19 supplemental and pandemic efforts Pharmacy Benefit Manager (BPM) transparency
AMGEN via HAGGERTY POLICY SOLUTIONS
2022 · third_quarter · Q3
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 H.R. 5376 Inflation Reduction Act - drug pricing provisions
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B Program
Filing targets: SENATE
CALIFORNIA LIFE SCIENCES via HAGGERTY POLICY SOLUTIONS
2022 · third_quarter · RR
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
AMGEN via HAGGERTY POLICY SOLUTIONS
2022 · second_quarter · Q2
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2022 · first_quarter · Q1
FDA Prescription Drug User Fee Reauthorization (not yet introduced) - accelerated approval issues, user fee agreements
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN via HAGGERTY POLICY SOLUTIONS
2022 · first_quarter · RR
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Lobbied to discuss with Congress the U.S. Trade Representative (USTR) delay on the decision to expand a World Trade Organization intellectual property waiver for COVID-19 vaccines to include COVID diagnostics and therapeutics and how the waiver should not be agreed to.
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Silicon Valley Bank collapse - Congressional oversight and potential action on policy issues surrounding the collapse.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FDA User Fee Reauthorization Act of 2022 - Reauthorization of PDUFA, MDUFA, and BSFUA - Accelerated approval, clinical trial diversity, medtech issues such as change control plans and foreign inspections certificates COVID 19 supplemental and pandemic efforts Pharmacy Benefit Manager (BPM) transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Inflation Reduction Act - all drug pricing provisions CMS proposed rule on Transitional Coverage of Emerging Technologies (TCET) Administration's EO on Prescription Drug Pricing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)